ClinicalTrials.gg

Program

Nucleotide Excision Repair-targeting Agent GSK5460025

In GlaxoSmithKline’s pipeline, Nucleotide excision repair targeting agent. Its studies are mostly in Colorectal Neoplasms, led by GlaxoSmithKline.

Furthest: phase 2, since Jul 4, 20251 company-led study, 1 open or runningNext primary completion: Sep 28, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 2since Jul 4, 2025Jul 4, 2025Sep 28, 2028phase 2 · NCT07213609
  • Named in GlaxoSmithKline’s own pipeline as GSK5460025, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 4, 2025First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT07213609 · 47 planned · United States, Canada, Denmark and more

Ahead

  1. Sep 28, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT07213609

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07213609Colorectal Neoplasms · United States, Canada, Denmark and more2RecruitingSep 28, 202847

How it is read

Names in the registry

  • “GSK5460025”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.